Market Overview

UPDATE: JP Morgan Initiates IMAX Corporation with Overweight, $30 PT on Growth Outlook

Share:
Related IMAX
Macquarie Analyst Comments On IMAX's Initial Steps Into VR
IMAX Announces New Revenue Share Agreement Plan With Chinese Partner

JP Morgan initiates its coverage on IMAX Corporation (NYSE: IMAX) with a rating of Overweight and a price target of $30.

JP Morgan notes, "We are initiating coverage of IMAX with an Overweight rating and $30 Dec 2012 price target. We find shares attractive for a high visibility, long-term growth story that is one of the few plays on emerging market box office growth. IMAX also benefits from a unique business model within the industry that delivers high profitability and recurring FCF generation with every screen added to its network. The company has established itself as a valuable brand to both consumers and filmmakers, which we expect will help maintain its advantaged position in the global theatrical industry."

IMAX closed at $24.03 on Friday.

Latest Ratings for IMAX

DateFirmActionFromTo
Mar 2016BenchmarkMaintainsBuy
Feb 2016WedbushUpgradesNeutralOutperform
Feb 2016JP MorganMaintainsNeutral

View More Analyst Ratings for IMAX
View the Latest Analyst Ratings

Posted-In: JP MorganAnalyst Color Price Target Initiation Intraday Update Analyst Ratings

 

Related Articles (IMAX)

View Comments and Join the Discussion!